Loading...
•
Mar 31, 2024
Day One Q1 2024 Earnings Report
Announced first quarter 2024 financial results and corporate progress.
Key Takeaways
Day One Biopharmaceuticals reported its first quarter 2024 financial results, including a net loss of $62.4 million and cash, cash equivalents, and short-term investments totaling $317.9 million.
OJEMDA is now approved and available in the U.S., with first prescriptions received.
Patients have begun enrolling in EveryDay Support From Day One program.
The Phase 3 FIREFLY-2/LOGGIC clinical trial continues to enroll at over 90 sites.
The Company received a rare pediatric disease priority review voucher from the FDA upon OJEMDA’s approval.
Forward Guidance
Results from the FIRELIGHT-1 Phase 1b and next steps are expected in the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...